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Targeting microrNas using 
nanotechnology in pulmonary diseases
microrNas (mirNas) are short non-coding rNas, which control 
gene expression post-transcriptionally by directly blocking trans-
lation of their target messenger rNas (mrNas) or by repressing 
protein production via mrNa destabilization. in the present times, 
the research in the area of targeting mirNas using antagomirs, 
which are also known as anti-mirs as potential therapeutic moi-
eties for the management of various chronic respiratory diseases, 
including asthma, chronic obstructive pulmonary disease (cOPd), 
and cystic fibrosis (cF), is gaining enormous attention. The ap-
plications and concepts of novel drug delivery systems such as 
nanoparticles can be employed in administering identified bio-
logical moieties, including specific antagomirs, which can help in 
achieving the therapeutic effectiveness by providing the targeted 
effects and overcoming the various problems like biofilms etc as-
sociated with various respiratory diseases.1
majority of the existing studies with nanoparticles containing 
anti-mirs were employed in the area of cancer research and lim-
ited information is available in the context of pulmonary diseases. 
Various types of nanoparticles such titanium dioxide or surface-
modified gold nanoparticles can be employed as a carrier to de-
liver various antagomirs to target the specific mirNas. Yung et 
al. demonstrated the efficacy of lipid nanoparticles composed of 
quaternary amine-tertiary amine cationic lipid combination (QT-
some) to deliver antimir-21, an oligonucleotide complementary 
to mir-21 in lung cancer. The prepared nanoparticles showed 
tumor regression, prolonged survival, and mir-21 target upreg-
ulation in an a549 xenograft mouse model.2 another study has 
shown the importance of lipid nanoparticles as a carrier for the 
microrNa-145 inhibitor in repairing pulmonary arteriopathy and 
improving cardiac function in rats with severe pulmonary arterial 
hypertension (PaH). Overall, their results indicated to be effec-
tive and having low toxicity with the pulmonary delivery of mir-
Na-145 inhibitor using functionalized cationic lipopolyamine 
nanoparticles.3
Polyethyleneimine and chitosan tripolyphosphate nanoparticles 
encapsulating hsa-mir-126 and hsa-mir-145 demonstrated effec-
tive delivery of the mirNas to cFBe41o- (human F508del cystic 
fibrosis transmembrane conductance regulator bronchial epitheli-
al) cells to modulate the gene expression in treating cystic fibrosis. 
These nanoparticles proved effective and biocompatible.4
Various new advancements in the pulmonary drug delivery 
include triggered release lipid nanocapsules, sponges and biomo-
lecular corona, which can be used to load various drugs. Various 
cell-derived membrane vesicles (cmVs) namely, microvesicles 
and exosomes also help in transporting various proteins and 
nucleic acids. Such recent developments may be employed to 
encapsulate various antagomirs in treating the pulmonary dis-
eases. recently, dahlman et al. developed a method to measure 
the biodistribution of various nanoparticles by formulating the 
nanoparticles carrying specific nucleic acid barcodes that can be 
sequenced to understand and quantify the particle biodistribution. 
Their study also provides information on the chemical structure 
and in-vivo delivery of nanoparticles, which can help in designing 
the nanoparticles with highly targeted effects in specific tissues 
and cells.5
mirNa-based therapy is expanding its horizons for the treat-
ment of pulmonary diseases where the nanotechnology is an ad-
vanced platform for delivering such therapeutic moieties including 
antagomirs to target various mirNas involved in the respiratory 
disease pathology. moreover, nanoparticles and similar vesicular 
drug delivery systems can also be used as carriers for small in-
terfering rNas (sirNas). This novel drug delivery system offers 
great benefits such as targeted effects, lesser side and unwanted ef-
fects with maximal efficacy and improved patient compliance. ap-
plication of nanotechnology still warrants attention and in-depth 
investigations especially the class focussed on targeting mirNas 
in various chronic inflammatory lung diseases, which can bring a 
new revolution to the pulmonary clinic.
Kamal dUa 1, 2, 3 *, 
dinesh K. cHeLLaPPaN 4, Gautam SiNGHVi 5, 
Terezinha de JeSUS aNdreOLi PiNTO 6, Gaurav GUPTa 7, 
Philip m. HaNSBrO 1, 2, 3
1discipline of Pharmacy, Graduate School of Health, University 
of Technology Sydney, Ultimo, australia; 2School of Biomedical 
Sciences and Pharmacy, The University of Newcastle, callaghan, 
australia; 3The Priority research centre for Healthy Lungs, 
Hunter medical research institute, Newcastle, australia; 
4department of Life Sciences, School of Pharmacy, international 
medical University, Bukit Jalil, malaysia; 5department of 
Pharmacy, Birla institute of Technology and Science (BiTS), 
Pilani, india; 6Faculty of Pharmaceutical Sciences, University 
of São Paulo, São Paulo, Brazil; 7School of Pharmaceutical 
Sciences, Jaipur National University, Jagatpura, india
*corresponding author: Kamal dua, discipline of Pharmacy, Graduate 
School of Health, University of Technology Sydney, Ultimo NSW 2007, 
australia. e-mail: kamalpharmacist02@gmail.com
References
1.  dua K, Shukla Sd, Tekade rK, Hansbro Pm. Whether a novel drug 
delivery system can overcome the problem of biofilms in respiratory dis-
eases? drug deliv Transl res 2017;7:179–87. 
2.  Yung Bc, Li J, Zhang m, cheng X, Li H, Yung em, et al. Lipid 














PROFF ID.indd   1 10/09/10   14:28
2 PaNmiNerVa medica mese 2018 
LeTTer TO THe ediTOr
Barcoded nanoparticles for high throughput in vivo discovery of targeted 
therapeutics. Proc Natl acad Sci USa 2017;114:2060–5. 
Conflicts of interest.—The authors certify that there is no conflict of inter-
est with any financial organization regarding the material discussed in the 
manuscript.
manuscript accepted: may 4, 2018. - manuscript received: april 17, 2018.
(Cite this article as: dua K, chellappan dK, Singhvi G, de Jesus andreoli 
Pinto T, Gupta G, Hansbro Pm. Targeting microrNas using nanotechnology 
in pulmonary diseases. Panminerva med 2018;60:000-000. dOi: 10.23736/
S0031-0808.18.03459-6)
Nanoparticles composed of Quaternary amine-Tertiary amine cationic 
Lipid combination (QTsome) for Therapeutic delivery of antimir-21 for 
Lung cancer. mol Pharm 2016;13:653–62. 
3.  mcLendon Jm, Joshi Sr, Sparks J, matar m, Fewell JG, abe K, et 
al. Lipid nanoparticle delivery of a microrNa-145 inhibitor improves 
experimental pulmonary hypertension. J control release 2015;210:67–
75. 
4.  mcKiernan PJ, cunningham O, Greene cm, cryan Sa. Targeting 
mirNa-based medicines to cystic fibrosis airway epithelial cells using 
nanotechnology. int J Nanomedicine 2013;8:3907–15.














PROFF ID.indd   1 10/09/10   14:28
